Our copayment assistance program is now open for new and renewal applications! Braintumorcopays.org #GBM

Blood test for brain cancer may be on horizon, new research finds pennstatehealthnews.org/2023/03/blood-…

Seeing great results in preclinical #dipg and #GBM models for #GB13 delivered by #CED! mayoclinic.org/medical-profes…

DOD Impact Award FUNDED! Excited to continue our ongoing collaboration with Mayo Clinic to bring GB-13 to the clinic for #DMG #DIPG #GBM

#GrayMay is a time to unite with people living with #braintumors & their loved ones to spread awareness about this deadly disease. Share quick, impactful stats about where we are in our mission to conquer & cure brain tumors, and inspire others to take action this month. #BTAM

Coming to the #SNOPeds SNO conference next month

Excited to have our collaborative research on GB13 as a #DMG treatment shared by Julian Rechberger #SNOPeds #DIPG

Today's the day! Proud to be a sponsor for BrainStorm Summit and working together to treat #DIPG #DMG

Almost time for #SNO2023! Randy Schrecengost will present our data of GB13 for treatment of #DMG and #GBM. Visit poster EXTH-54. targepeutics.com/targepeutics-s…

So exciting to be collaborating with Alireza Mansouri

Huge congrats to Alireza Mansouri and Targepeutics for joining forces! This W. W. Smith Trust grant is a massive win for #Glioblastoma research. Can't wait to see the progress you make on liquid biopsy! Penn State Neurosurgery #GBM

We want to thank Dr. Giselle Sholler Giselle Sholler and the entire Beat Childhood Cancer team for giving us this opportunity to talk about GB13, our promising lead therapeutic for #DIPG #DMG.

Thank you for giving Sil Lutkewitte the chance to share about our journey to the clinic. Targepeutics is a proud sponsor of BrainStorm Summit #DMG #DIPG

targepeutics.com/help_and_hope_… Targepeutics was happy to be on the Help and Hope Happen Here Podcast.

Targepeutics is excited for the Focused Ultrasound Foundation funded research collaboration at CU Anschutz Medical Campus with Adam Green and Mark Borden. Can GB13 be delivered to DIPG tumors via FUS?

targepeutics.com/news/

Big news from Targepeutics! The FDA has granted Rare Pediatric Disease designation for our therapy GB13, targeting pediatric diffuse high-grade glioma. This milestone brings us closer to delivering hope to families. Learn more: targepeutics.com/news/ #RareDisease #DMG #DIPG

A great Beat Childhood Cancer annual meeting. Grateful to Dr Sholler, BCC and Four Diamonds for the continued support! #DIPG #DMG

Words can’t express the gratitude to Tough2gether - Against DIPG and DDRFA and the continued support of our upcoming #DIPG #DMG trial with GB13. #behindtheribbon

🚨 Big news! We’re welcoming the Yuvaan Tiwari Foundation Foundation as a new strategic partner in our fight against #DIPG. Their investment advances GB13 into clinical trials. Together, we’re fighting one of the deadliest pediatric brain cancers with bold science and deep purpose.#DMG